Deutsche Bank
ARTV

Deutsche Bank’s Artiva Biotherapeutics ARTV Stock Holding History

Deutsche Bank’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,383
Closed -$5.11K – 3761
2025
Q2 		$5.11K Sell
3,383
-18,040
-84% -$37.9K ﹤0.01% 3524
2025
Q1 		$64.3K Hold
21,423
– – ﹤0.01% 3321
2024
Q4 		$216K Buy
+21,423
New +$257K ﹤0.01% 3065

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank's ARTV Position: Q3 2025 in Review

Deutsche Bank sold out of Artiva Biotherapeutics (ARTV) in Q3 2025, closing a stake of 3,383 shares — an estimated $5.11K sold.

Deutsche Bank first reported a position in ARTV in Q4 2024 and held it in 3 quarters. The position peaked at $216K in Q4 2024. 40 funds tracked by Wall St. Rank hold ARTV as of Q3 2025.

  • Deutsche Bank reported no remaining Artiva Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Deutsche Bank sold 3,383 Artiva Biotherapeutics shares in Q3 2025, an estimated $5.11K.
  • Deutsche Bank first reported a position in Artiva Biotherapeutics in Q4 2024 and held it in 3 quarters.
  • Deutsche Bank's Artiva Biotherapeutics position peaked at $216K in Q4 2024.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2025.

Based on Deutsche Bank's 13F filing for Q3 2025, filed 13 Nov 2025.